Absolute and relative contraindications to pegylated‐interferon or ribavirin in the US general patient population with chronic hepatitis C: results from a US database of over 45 000 HCV‐infected, evaluated patients
- 7 January 2013
- journal article
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 37 (4), 473-481
- https://doi.org/10.1111/apt.12200
Abstract
Chronic hepatitis C (HCV) treatment with pegylated-interferon (PEG-IFN)/ribavirin (RBV) is often limited by preexisting medical, psychiatric and psychosocial contraindications. However, limited data exist in general patient populations. To evaluate the percentage of HCV-infected patients in the general US population who may have contraindications to PEG-IFN/RBV. The General Electric (GE) Centricity dataset was used to screen the US population between 2004 and 2009 for HCV infection and contraindications to PEG-IFN/RBV. HCV diagnosis and contraindications were identified using ICD-9-CM codes or laboratory values. Only patients with an encounter 180 days prior to HCV diagnosis were included. Demographic differences were calculated using Pearson's chi-squared test. Frequencies and percentages for absolute and relative contraindications to PEG-IFN and/or RBV were determined and proportions and rates/1000 person-months were calculated. A total of 15 561 021 patients were screened, and 45 690 (0.3%) were HCV-positive and were evaluated. Those with contraindications were significantly younger, female, White, not currently married and receiving Medicare or Medicaid coverage (all P < 0.0001). 17.3% had at least one contraindication to PEG-IFN/RBV (5.5 events/1000 person-months); bipolar disorder (6.5%), anaemia (Hgb < 10 g/dL; 5.9%), pregnancy (1.9%) and neutropenia (neutrophils <750 cells/mm(3) ; 1.2%) were most frequently cited. Approximately, 17% of HCV-infected patients in the general US population had at least one contraindication to PEG-IFN/RBV. Most contraindications were relative and potentially modifiable. Clinical assessment of contraindications as relative and/or modifiable should be considered and used to determine if patients could benefit from current PEG-IFN-containing triple therapy or future PEG-IFN- or RBV-free regimens.Keywords
This publication has 20 references indexed in Scilit:
- An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver DiseasesHepatology, 2011
- Hepatitis C virus infection in USA: an estimate of true prevalenceLiver International, 2011
- Telaprevir with Peginterferon and Ribavirin for Chronic HCV Genotype 1 InfectionThe New England Journal of Medicine, 2009
- The global burden of hepatitis CLiver International, 2009
- Diagnosis, management, and treatment of hepatitis C: An updateHepatology, 2008
- Rate and predictors of treatment prescription for hepatitis CGut, 2007
- Reasons for non‐treatment of hepatitis C in veterans in careJournal of Viral Hepatitis, 2005
- Hepatitis C Virus and Human Immunodeficiency Virus Coinfection in an Urban Population: Low Eligibility for Interferon TreatmentClinical Infectious Diseases, 2003
- Hepatitis C Virus InfectionThe New England Journal of Medicine, 2001
- Interferon Alfa-2b Alone or in Combination with Ribavirin as Initial Treatment for Chronic Hepatitis CThe New England Journal of Medicine, 1998